American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S26-S32 , September 2007

Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States

  • Denise J. Jamieson, MD, MPH

      Affiliations

    • Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA
    • Corresponding Author InformationReprints: Denise J. Jamieson, MD MPH, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K34, Atlanta, GA 30341.
    • ,
  • Jill Clark, MPH

      Affiliations

    • Northrop Grumman Information Technology, CDC Information Technology Support, Atlanta, GA
    • ,
  • Athena P. Kourtis, MD, PhD, MPH

      Affiliations

    • Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA
    • ,
  • Allan W. Taylor, MD, MPH

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Margaret A. Lampe, MPH, RN

      Affiliations

    • Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Mary Glenn Fowler, MD, MPH

      Affiliations

    • Johns Hopkins Medical School, Department of Pathology, Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda
    • ,
  • Lynne M. Mofenson, MD

      Affiliations

    • Pediatric, Adolescent, and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.

Received 14 December 2006 ,Accepted 31 March 2007.

References 

  1. Centers for Disease Control and Prevention. Unexplained immunodeficiency and opportunistic infections in infants: New York, New Jersey, California. MMWR Morb Mortal Wkly Rep. 1982;31:665–667
  2. Cowan MJ, Hellmann D, Chudwin D, Wara DW, Chang RS, Ammann AJ. Maternal transmission of acquired immune deficiency syndrome. Pediatrics. 1984;73:382–386
  3. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection: United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55:592–597
  4. Centers for Disease Control and Prevention. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1985;34:721–722
  5. Barbacci MB, Dalabetta GA, Repke JT, et al. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis. 1990;17:122–126
  6. Minkoff HL, Landesman SH. The case for routinely offering prenatal testing for human immunodeficiency virus. Am J Obstet Gynecol. 1988;159:793–796
  7. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep. 1994;43:1–20
  8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180
  9. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep. 1995;44:1–15
  10. Institute of Medicine. Reducing the odds: preventing perinatal transmission of HIV in the United States. Washington, DC: National Academy Press; 1999;
  11. Human immunodeficiency virus screening: joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Pediatrics. 1999;104:128
  12. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep. 2001;50:63–85
  13. Centers for Disease Control and Prevention. HIV testing among pregnant women: United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep. 2002;51:1013–1016
  14. Gerberding JL, Jaffe HW. ”Dear Colleague” letter. 2003;April 22, Last accessed: July 29, 2006 Available at: http://www.cdc.gov/hiv/projects/perinatal/2003/letter.htm.
  15. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17
  16. Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol. 2003;102:782–790
  17. Warren B, Glaros RHS. Residual perinatal HIV transmissions in 25 births occurring in New York state. In: Presentation at the 2005 National HIV Prevention Conference, Atlanta, GA. 2005;
  18. Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep. 2006;55:1–17
  19. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802
  20. Bulterys M, Jamieson DJ, O’Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA. 2004;292:219–223
  21. American College of Obstetricians and Gynecologists. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations: ACOG committee opinion number 304. Obstet Gynecol. 2004;104:1119–1124
  22. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep. 1994;43:285–287
  23. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States: 7-6-2006 update. Last accessed: August 22, 2006. Available at: http://AIDSinfo.nih.gov.
  24. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 1998;47:1–30
  25. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Last accessed: October 23, 2006. Available at: http://AIDSinfo.nih.gov.
  26. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group protocol 076. J Infect Dis. 1998;177:557–564
  27. Jamieson DJ, Read J, Kourtis AP, Durant TM, Lampe M, Dominguez K. Cesarean delivery for HIV-infected women: Recommendations and controversies. Am J Obstet Gynecol. 2006;

PII: S0002-9378(07)00487-5

doi: 10.1016/j.ajog.2007.03.087

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S26-S32 , September 2007

Article Tools